Related Experiment Video
Updated: Oct 26, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
A new approach to treat type 2 diabetes - Targeting a non-insulin dependent pathway
1Atrogi AB, Tomtebodavägen 6, 171 65 Solna, Sweden.
Abstract:
Diabetes is one of the most urgent healthcare challenges that we are currently facing, and there is a growing need for medications which can manage the condition on a long-term basis. Researchers at Stockholm University working with startup Atrogi AB have developed a novel approach which targets the β2 adrenergic receptors, circumventing the failing insulin signaling pathway. This unique way of addressing the problem potentially opens the way to a new class of diabetes medications.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: The Receptor and Signaling Pathways

